ArriVent BioPharma (AVBP) PT Raised to $45 at Citi
Tweet
Share
E-mailGet Alerts AVBP Hot Sheet
Price: $30.75 +0.79%
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 16 | New: 22
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 16 | New: 22
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $45.00 (from $33.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- Obayashi Corporation (1802:JP) PT Lowered to JPY3,300 at Nomura/Instinet
- ENEOS Holdings Inc (5020:JP) (JXHLY) PT Raised to JPY1,800 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
